Developing and applying a stochastic dynamic population model for chronic obstructive pulmonary disease
- PMID: 22152172
- DOI: 10.1016/j.jval.2011.06.008
Developing and applying a stochastic dynamic population model for chronic obstructive pulmonary disease
Abstract
Objectives: To develop a stochastic population model of disease progression in chronic obstructive pulmonary disease (COPD) that includes the effects of COPD exacerbations on health-related quality of life, costs, disease progression, and mortality and can be used to assess the effects of a wide range of interventions.
Methods: The model is a multistate Markov model with time varying transition rates specified by age, sex, smoking status, COPD disease severity, and/or exacerbation type. The model simulates annual changes in COPD prevalence due to COPD incidence, exacerbations, disease progression (annual decline in the forced expiratory volume in 1 second as percentage of the predicted value), and mortality. The main outcome variables are quality-adjusted life years, total exacerbations, and COPD-related health care costs. Exacerbation-related input parameters were based on quantitative meta-analysis. All important model parameters are entered into the model as probability distributions. To illustrate the potential use of the model, costs and effects were calculated for 3-year implementation of three different COPD interventions, one pharmacologic, one on smoking cessation, and one on pulmonary rehabilitation using a time horizon of 10 years for reporting outcomes.
Results: Compared with minimal treatment the cost/quality-adjusted life year was €8,300 for the pharmacologic intervention, €10,800 for the smoking cessation therapy, €8,700 for the combination of the pharmacologic intervention and the smoking cessation therapy, and €17,200 for the pulmonary rehabilitation program. The probability of the interventions to be cost-effective at a ceiling ratio of €20,000 varied from 58% to 100%.
Conclusions: The COPD model provides policy makers with information about the long-term costs and effects of interventions over the entire chain of care, from primary prevention to care for very severe COPD and includes uncertainty around the outcomes.
Copyright © 2011 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.
Similar articles
-
A dynamic population model of disease progression in COPD.Eur Respir J. 2005 Aug;26(2):223-33. doi: 10.1183/09031936.05.00122004. Eur Respir J. 2005. PMID: 16055869
-
Cost-effectiveness analysis of roflumilast/tiotropium therapy versus tiotropium monotherapy for treating severe-to-very severe COPD.J Med Econ. 2011;14(6):805-15. doi: 10.3111/13696998.2011.623204. Epub 2011 Oct 12. J Med Econ. 2011. PMID: 21992217
-
It's about time--directing our attention toward modifying the course of COPD.Respir Med. 2008 Jun;102 Suppl 1:S37-48. doi: 10.1016/S0954-6111(08)70006-4. Respir Med. 2008. PMID: 18582796 Review.
-
Cost-effectiveness models for chronic obstructive pulmonary disease: cross-model comparison of hypothetical treatment scenarios.Value Health. 2014 Jul;17(5):525-36. doi: 10.1016/j.jval.2014.03.1721. Epub 2014 May 14. Value Health. 2014. PMID: 25128045
-
The value of forced expiratory volume in 1 second decline in the assessment of chronic obstructive pulmonary disease progression.Am J Med. 2006 Oct;119(10 Suppl 1):4-11. doi: 10.1016/j.amjmed.2006.08.002. Am J Med. 2006. PMID: 16996894 Review.
Cited by
-
A systematic review of whole disease models for informing healthcare resource allocation decisions.PLoS One. 2023 Sep 14;18(9):e0291366. doi: 10.1371/journal.pone.0291366. eCollection 2023. PLoS One. 2023. PMID: 37708188 Free PMC article.
-
A Novel Method for Analysing Frequent Observations from Questionnaires in Order to Model Patient-Reported Outcomes: Application to EXACT® Daily Diary Data from COPD Patients.AAPS J. 2019 Apr 26;21(4):60. doi: 10.1208/s12248-019-0319-9. AAPS J. 2019. PMID: 31028495 Free PMC article.
-
Improving inhaler adherence in patients with chronic obstructive pulmonary disease: a cost-effectiveness analysis.Respir Res. 2014 Jun 14;15(1):66. doi: 10.1186/1465-9921-15-66. Respir Res. 2014. PMID: 24929799 Free PMC article. Clinical Trial.
-
Projecting the COPD population and costs in England and Scotland: 2011 to 2030.Sci Rep. 2016 Sep 1;6:31893. doi: 10.1038/srep31893. Sci Rep. 2016. PMID: 27583987 Free PMC article.
-
Features of self-management interventions for people with COPD associated with improved health-related quality of life and reduced emergency department visits: a systematic review and meta-analysis.Int J Chron Obstruct Pulmon Dis. 2017 Jun 8;12:1705-1720. doi: 10.2147/COPD.S133317. eCollection 2017. Int J Chron Obstruct Pulmon Dis. 2017. PMID: 28652723 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical